Total Payments
$2,163
2024 Payments
$203.62
Companies
13
Transactions
39
Medicare Patients
2,765
Medicare Billing
$550,055
Payment Breakdown by Category
Food & Beverage$2,069 (95.6%)
Education$94.12 (4.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,069 | 33 | 95.6% |
| Education | $94.12 | 6 | 4.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $657.70 | 13 | $0 (2023) |
| Gilead Sciences, Inc. | $499.48 | 5 | $0 (2019) |
| La Jolla Pharmaceutical Company | $218.17 | 2 | $0 (2024) |
| Allergan, Inc. | $164.09 | 4 | $0 (2020) |
| AbbVie, Inc. | $159.50 | 6 | $0 (2018) |
| GlaxoSmithKline, LLC. | $121.83 | 1 | $0 (2023) |
| Oxford Immunotec USA Inc | $113.86 | 1 | $0 (2019) |
| Medtronic, Inc. | $81.82 | 1 | $0 (2024) |
| Microgenics Corporation | $63.39 | 1 | $0 (2018) |
| ViiV Healthcare Company | $36.62 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $203.62 | 2 | La Jolla Pharmaceutical Company ($121.80) |
| 2023 | $392.05 | 7 | Merck Sharp & Dohme LLC ($135.96) |
| 2022 | $175.67 | 6 | Merck Sharp & Dohme LLC ($159.43) |
| 2020 | $137.88 | 2 | Allergan, Inc. ($137.88) |
| 2019 | $500.80 | 6 | Gilead Sciences, Inc. ($271.56) |
| 2018 | $199.42 | 3 | Merck Sharp & Dohme Corporation ($124.99) |
| 2017 | $553.78 | 13 | Gilead Sciences Inc ($227.92) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $121.80 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 04/10/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $81.82 | General |
| Category: EndoVenous Therapies | ||||||
| 10/04/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $96.37 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/22/2023 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Education | In-kind items and services | $10.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/06/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: Infections and Infectious Diseases | ||||||
| 05/05/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: HIV | ||||||
| 04/27/2023 | Merck Sharp & Dohme LLC | ZINPLAVA (Biological) | Education | In-kind items and services | $10.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/22/2023 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $114.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/26/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: VACCINES | ||||||
| 12/01/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $108.52 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/18/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $3.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/10/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Education | In-kind items and services | $21.74 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/04/2022 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA, RECARBRIO | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/20/2022 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Education | In-kind items and services | $21.74 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/14/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 04/09/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/12/2020 | Allergan, Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/12/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/14/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $102.68 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/31/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.78 | General |
| 06/26/2019 | Oxford Immunotec USA Inc | TSPOT TB TEST (Device) | Food and Beverage | In-kind items and services | $113.86 | General |
| Category: Diagnostic Test | ||||||
| 05/22/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $122.91 | General |
| 01/24/2019 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: HCV | ||||||
| 11/13/2018 | Microgenics Corporation | Procalcitonin (PCT) (Device) | Food and Beverage | Cash or cash equivalent | $63.39 | General |
| Category: Biomarkers | ||||||
| 11/11/2018 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $11.04 | General |
| Category: Virology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 565 | 1,009 | $429,070 | $119,018 |
| 2022 | 10 | 746 | 1,290 | $540,977 | $144,478 |
| 2021 | 11 | 761 | 1,334 | $541,242 | $147,675 |
| 2020 | 7 | 693 | 1,238 | $496,984 | $138,884 |
Total Patients
2,765
Total Services
4,871
Medicare Billing
$550,055
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 309 | 713 | $243,846 | $76,729 | 31.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 115 | 122 | $80,886 | $19,087 | 23.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 42 | 49 | $47,530 | $9,247 | 19.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 39 | $24,765 | $6,220 | 25.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 49 | $11,613 | $3,511 | 30.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 26 | $11,960 | $2,582 | 21.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $8,470 | $1,642 | 19.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 340 | 835 | $285,587 | $76,270 | 26.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 156 | 166 | $110,058 | $29,451 | 26.8% |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | Office | 2022 | 26 | 26 | $23,400 | $11,816 | 50.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 38 | 43 | $41,710 | $8,089 | 19.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 33 | $20,955 | $4,681 | 22.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 62 | 67 | $15,840 | $4,283 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 45 | $20,700 | $4,238 | 20.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 37 | 37 | $14,689 | $3,582 | 24.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 16 | $5,200 | $1,306 | 25.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 17 | 22 | $2,838 | $762.02 | 26.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 322 | 803 | $274,546 | $75,190 | 27.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 154 | 162 | $107,406 | $29,308 | 27.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 59 | 66 | $45,236 | $12,953 | 28.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 41 | 67 | $29,852 | $8,099 | 27.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 85 | 112 | $26,544 | $7,311 | 27.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 43 | $25,787 | $6,652 | 25.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $10,706 | $2,772 | 25.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 25 | $7,687 | $2,116 | 27.5% |
About Dr. Jorge Bernett, M.D
Dr. Jorge Bernett, M.D is a Infectious Disease healthcare provider based in Walnut Creek, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1366460081.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jorge Bernett, M.D has received a total of $2,163 in payments from pharmaceutical and medical device companies, with $203.62 received in 2024. These payments were reported across 39 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($2,069).
As a Medicare-enrolled provider, Bernett has provided services to 2,765 Medicare beneficiaries, totaling 4,871 services with total Medicare billing of $550,055. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Walnut Creek, CA
- Active Since 07/18/2006
- Last Updated 01/30/2008
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1366460081
Products in Payments
- ZERBAXA (Drug) $406.90
- Epclusa (Drug) $233.73
- XERAVA (Drug) $218.17
- DALVANCE (Drug) $151.20
- SHINGRIX (Biological) $121.83
- ZINPLAVA (Biological) $117.28
- Genvoya (Drug) $116.06
- RECARBRIO (Drug) $114.26
- TSPOT TB TEST (Device) $113.86
- Viekira (Drug) $108.74
- VENASEAL (Device) $81.82
- Procalcitonin (PCT) (Device) $63.39
- Mavyret (Drug) $50.76
- CABENUVA (Biological) $24.48
- DIFICID (Drug) $19.26
- Arikayce (Drug) $16.24
- Fetroja (Drug) $13.41
- AVYCAZ (Drug) $12.89
- TRIUMEQ (Drug) $12.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Walnut Creek
Dr. Ronald Wasserman, M.d, M.D
Infectious Disease — Payments: $3,199
Infectious Disease $3,199
Dr. Joshua Perlroth, M.d, M.D
Infectious Disease — Payments: $1,104
Infectious Disease $1,104
Jennifer Cheng, D.o, D.O
Infectious Disease — Payments: $940.94
Infectious Disease $940.94
Konark Sharma, M.d, M.D
Infectious Disease — Payments: $836.26
Infectious Disease $836.26
Nimisha Mishra-Shukla, Md, MD
Infectious Disease — Payments: $705.50
Infectious Disease $705.50
Dr. Bela Chheda, M.d, M.D
Infectious Disease — Payments: $308.18
Infectious Disease $308.18